Presenting at the TRP Summit is an exciting opportunity to share the progress of 177Lu-AKIR001 with the international radiopharmaceutical community. The therapy holds the potential to become a first-in-class treatment for multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. With clinical trials set to begin at Karolinska University Hospital in Sweden in early 2025, we are thrilled to contribute to discussions shaping the future of targeted cancer therapies.

The start of the Phase 1 clinical trial is a significant milestone for Akiram and an important step forward in molecular radiation therapy. We are excited to collaborate with Karolinska University Hospital and are confident in AKIR001's potential to improve treatment outcomes for patients.

177Lu-AKIR001 has the potential to transform how we treat hard-to-treat tumors and could represent a major advancement in precision medicine.

177Lu-AKIR001 has shown great preclinical potential to transform the treatment of CD44v6-expressing tumors. We are looking forward to starting phase 1 studies later this fall, with the goal of offering new, targeted treatment options for patients with hard-to-treat cancers. The selection of our presentation as one of the top-rated talks is a clear recognition of the promising research, and we are excited to share the results with the international scientific community.

With this agreement and the GMP production of the affinity carrier in place, we have everything needed to apply for a first-in-human clinical study in 2024. We are very excited and strongly motivated to progress this important project in close collaboration with our clinical colleagues at Karolinska University Hospital.

It is with great pleasure that we welcome Anna Törner and Peder Walberg to Akiram's board. We are facing important developmental steps, and their investment and commitment to the company are strong indications of confidence in our strategic direction and our ability to realize our goals in cancer treatment.

The grant is a testament to our commitment to pioneering cancer treatments. This generous support from the Erling-Persson Foundation allows us to advance our mission, offering hope and potential solutions to individuals suffering from incurable cancers.

We are honored to have the opportunity to present at the Annual EANM Congress. We look forward to sharing promising data about our drug candidate, which we believe holds the potential to significantly impact patient care and radiopharmaceutical sciences in the future. Participating in this global conversation that's shaping the future of Nuclear Medicine is genuinely exciting.

We would like to thank Sciety and all those who have participated in this successful issue for the great confidence in Akiram and our drug candidate. We now have the means to continue our work at full speed and take the next important steps on our exciting journey. We are very eager to continue the development of our drug candidate and to initiate phase I clinical studies.